UTHR
United Therapeutics Corporation
536.40$
-1.0%
vs. previous close
Closing price · As of: Oct 5, 2026
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -56.5% | +149.8% | -38.3% | +62.4% | -9.5% | +35.2% | -58.4% | +193.2% | -38.4% | +33.8% | -32.3% | – | |
| – | +3.0% | +9.5% | +24.7% | +2.1% | +3.1% | +0.5% | +6.6% | +3.8% | +4.1% | -0.9% | +7.1% | – | |
| – | -21.3% | +54.2% | +94.1% | -16.1% | -35.3% | +17.8% | +18.9% | +3.4% | -0.3% | -13.1% | +128.0% | – | |
| – | -299.3% | – | -373.4% | – | -132.3% | – | -360.3% | – | -188.6% | – | -1,100.8% | – | |
| – | +19.8% | -51.5% | +18.1% | +69.6% | +13.3% | -13.6% | -17.0% | +238.4% | -17.9% | -41.7% | +7.1% | – | |
| – | – | +1,646.6% | -110.9% | +43.6% | +7.2% | +33.7% | +82.1% | – | -261.5% | – | -88.2% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -50.0% | +999,900.0% | -98.9% | -96.5% | -25.0% | +5,000.0% | -66.0% | +19,130.8% | – | -34,190.9% | -96.1% | – | |
| – | – | – | – | – | +0.0% | +0.0% | +100.0% | -100.0% | – | – | – | – | |
| – | -1,321.1% | +1,050.9% | -95.5% | +33.5% | +16.5% | +25.6% | +111.7% | +381.4% | – | -1,608.5% | – | – | |
| – | +147.5% | -56.2% | +137.9% | +90.2% | -27.7% | +41.5% | -251.4% | – | – | -322.5% | – | – | |
| – | -74.3% | +369.9% | -44.7% | +60.7% | -15.4% | +51.8% | -66.5% | +171.5% | -50.7% | +109.2% | -43.3% | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.